Vascular changes after intra-bleb injection of bevacizumab.
OBJECTIVE
To illustrate changes in bleb vascularity after subconjunctival bevacizumab injection.


METHODS
Longitudinal changes in bleb vascularity were followed over 6 months pre and postbevacizumab injection.


RESULTS
Bleb vascularity associated with increased scarring activity was observed 10 days postcataract surgery in an eye that had undergone trabeculectomy 3 months previously. A single subconjunctival avastin injection led to a dramatic reduction in bleb vascularity for 6 weeks. With continued steroids, a diffuse, healthy, well functioning bleb with minimal scar tissue was present at 6 months.


CONCLUSIONS
Subconjunctival injection of bevacizumab reduced bleb vascularity and may provide an adjunct to current antifibrosis therapy. Further studies to establish the effect of bevacizumab on postoperative scaring are warranted.
Centre for Eye Research Australia, University of Melbourne, Melbourne, Vic 8002, Australia.
Michael A
MA
Coote
Jonathan B
JB
Ruddle
Queena
Q
Qin
Jonathan G
JG
Crowston
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva / Q000098:blood supply* / Q000473:pathology; D005355:Fibrosis / Q000188:drug therapy; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D013524:Surgical Flaps / Q000098:blood supply*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab